Clinical trials
BCLC Stage C Hepatocellular Carcinoma clinical trials
Below are recruiting bclc stage c hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 116 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06602011Recruiting
Triple therapy for advanced liver cancer with bile duct invasion
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
Fuzhou, FujianAges 18–75 - NCT06561399Recruiting
Triple therapy followed by radiation for liver cancer
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Fuzhou, FujianAges 18–75 - NCT07547553RecruitingPhase 1/Phase 2
HH-009 for Advanced Liver Cancer with FGF19 Marker
This trial tests a new drug called HH-009 for advanced or inoperable liver cancer (hepatocellular carcinoma, or HCC) that has a specific genetic marker called FGF19. The drug is designed to target this marker and may help slow or shrink the cancer in people whose disease has gotten worse despite previous treatment.
Bengbu, AnhuiAges 18–75 - NCT06397222RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06309485RecruitingPhase 2
Study of WGI-0301 for advanced liver cancer
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06294548RecruitingPhase 1/Phase 2
Valemetostat plus atezolizumab and bevacizumab for advanced liver cancer
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
Birmingham, AlabamaAges 18 years+ - NCT06215651RecruitingPhase 2
Testing cadonilimab and lenvatinib before liver cancer surgery
This study tests whether a combination of two drugs (cadonilimab and lenvatinib) can shrink liver cancer enough to make it removable by surgery for people whose cancer was previously too advanced for surgery. You may qualify if your cancer hasn't spread far, you haven't had treatment before, and your liver is still working fairly well.
Beijing, Beijing MunicipalityAges 18–75 - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT05985798RecruitingPhase 3
Immunotherapy plus TACE vs. Targeted Therapy plus TACE for Advanced Liver Cancer
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT05882370RecruitingPhase 2
Immunotherapy plus TIPS for liver cancer with blocked portal vein
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
Guangzhou, GuangdongAges 18–75 - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05608200RecruitingPhase 3
Lenvatinib plus immunotherapy with TACE versus standard TACE
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT05476432RecruitingPhase 3
One-day versus two-day chemotherapy for unresectable liver cancer
This study compares two schedules of chemotherapy to treat liver cancer that cannot be removed with surgery. It aims to see whether the shorter schedule works about as well, with similar safety.
Foshan, GuangdongAges 18–75 - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+ - NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT07814014Recruiting
Systemic therapy options for liver cancer
This trial studies which systemic treatments (medicines that travel through the blood to reach cancer cells) work best for patients with advanced liver cancer. It aims to find the most effective approach to slow tumor growth and improve quality of life.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new BCLC Stage C Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bclc stage c hepatocellular carcinoma?
- Yes. Clin2 currently lists 116 recruiting bclc stage c hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bclc stage c hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bclc stage c hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- BCLC Stage B Hepatocellular Carcinoma
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Hepatocellular Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.